

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Endocrine disease				
Diabetes	Glucagon-like peptide-1 receptor (GLP-1 receptor)	<p>A study <i>in vitro</i> and in animals identified GLP-1 receptor agonists that may be useful for treating type 2 diabetes. In mice and cynomolgus monkeys, PEGylated and sterically constrained GLP-1 peptide derivatives lowered blood glucose levels from 24 hours up to 6 days ($p < 0.001$ for mice, $p < 0.05$ for monkeys). Next steps include testing subcutaneous administration of the agonists in diabetic patients.</p> <p>Byetta exenatide, a GLP-1 receptor agonist from Amylin Pharmaceuticals Inc. and Eli Lilly and Co., is marketed to treat diabetes.</p>	Patented; available for licensing	<p>Miranda, L.P. <i>et al.</i> <i>J. Med. Chem.</i>; published online April 15, 2008; doi:10.1021/jm701522b</p> <p>Contact: Les P. Miranda, Amgen Inc., Thousand Oaks, Calif. e-mail: lesm@amgen.com</p>